Chengfei Liu

Photo of Chengfei Liu
Title(s)Associate Professor, MED: Urologic Surgery
SchoolSchool of Medicine
Address4645 2nd Ave. Research III
CA 95817
Phone916-734-5902
vCardDownload vCard
    Other Positions
    Title(s)Associate Professor in Residence, MED: Urologic Surgery


    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer. Int J Mol Sci. 2026 Jul 02; 27(13). Qu H, Xu P, Yang JC, Wei F, Zhao J, Wang L, Corey E, Mitsiades N, Lam K, Iczkowski KA, Li Y, Gao AC, Dall'Era M, Liu C. PMID: 42450213; PMCID: PMC13361713.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2026 May 04; 25(5):786-798. Leslie AR, Ning S, Sharifi M, Schaaf ZA, Maine JP, Lou W, Leslie KD, Liu C, Xu H, Lombard AP, Chen HW, Parikh M, Dall'Era M, Gao AC. PMID: 41347288; PMCID: PMC12795166.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    3. Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer. Cancers (Basel). 2025 Sep 30; 17(19). Xu P, Qu H, Yang JC, Wei F, Zhao J, Tang M, Wang L, Nip C, Li H, Gao AC, Lam K, Dall'Era M, Li Y, Liu C. PMID: 41097714; PMCID: PMC12524111.
      View in: PubMed   Mentions:
    4. Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer. Cancers (Basel). 2025 Jun 12; 17(12). Sharifi M, Armstrong CM, Ning S, Leslie AR, Schaaf ZA, Maine JP, Lou W, Li PK, Xu H, Liu C, Gao AC. PMID: 40563609; PMCID: PMC12190948.
      View in: PubMed   Mentions: 1  
    5. Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2025 May; 44(17):1204-1206. Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN, Evans CP, Hammock BD, Liu C. PMID: 40210759; PMCID: PMC12355828.
      View in: PubMed   Mentions:    Fields:    
    6. LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Res. 2024 11 04; 84(21):3617-3628. Ning S, Armstrong CM, Xing E, Leslie AR, Gao RY, Sharifi M, Schaaf ZA, Lou W, Han X, Xu DH, Yang R, Cheng J, Mohammed S, Mitsiades N, Liu C, Lombard AP, Wu CY, Cheng X, Li PK, Gao AC. PMID: 39088701; PMCID: PMC11534543.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    7. PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Res Commun. 2024 11 01; 4(11):2976-2985. Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine JP, Lou W, Lombard AP, Liu C, Yu AM, Mitsiades N, Gao AC. PMID: 39440945; PMCID: PMC11577557.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    8. Correction: Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2024 10 01; 15:677-678. Liu C, Armstrong C, Zhu Y, Lou W, Gao AC. PMID: 39352799; PMCID: PMC11444333.
      View in: PubMed   Mentions:    Fields:    
    9. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nat Commun. 2024 08 05; 15(1):6626. Xu P, Yang JC, Chen B, Ning S, Zhang X, Wang L, Nip C, Shen Y, Johnson OT, Grigorean G, Phinney B, Liu L, Wei Q, Corey E, Tepper CG, Chen HW, Evans CP, Dall'Era MA, Gao AC, Gestwicki JE, Liu C. PMID: 39103353; PMCID: PMC11300456.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    10. Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene. 2024 07; 43(30):2325-2337. Chen B, Xu P, Yang JC, Nip C, Wang L, Shen Y, Ning S, Shang Y, Corey E, Gao AC, Gestwicki JE, Wei Q, Liu L, Liu C. PMID: 38877132; PMCID: PMC11286220.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    11. DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer. Oncogene. 2024 05; 43(19):1399-1410. Guo S, Miao M, Wu Y, Pan D, Wu Q, Kang Z, Zeng J, Zhong G, Liu C, Wang J. PMID: 38480915.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    12. IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience. 2024 Feb 16; 27(2):108984. Leslie AR, Ning S, Armstrong CM, D'Abronzo LS, Sharifi M, Schaaf ZA, Lou W, Liu C, Evans CP, Lombard AP, Gao AC. PMID: 38327800; PMCID: PMC10847745.
      View in: PubMed   Mentions: 8  
    13. CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines. 2023 Dec 16; 11(12). Nip C, Wang L, Liu C. PMID: 38137547; PMCID: PMC10741515.
      View in: PubMed   Mentions: 14  
    14. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers (Basel). 2023 Nov 03; 15(21). Schaaf ZA, Ning S, Leslie AR, Sharifi M, Han X, Armstrong C, Lou W, Lombard AP, Liu C, Gao AC. PMID: 37958444; PMCID: PMC10650051.
      View in: PubMed   Mentions: 4  
    15. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. J Immunother Cancer. 2023 05; 11(5). Xu P, Yang JC, Chen B, Nip C, Van Dyke JE, Zhang X, Chen HW, Evans CP, Murphy WJ, Liu C. PMID: 37147019; PMCID: PMC10163595.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    16. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. Pharmacol Res. 2023 03; 189:106692. Xu P, Yang JC, Ning S, Chen B, Nip C, Wei Q, Liu L, Johnson OT, Gao AC, Gestwicki JE, Evans CP, Liu C. PMID: 36773708; PMCID: PMC10162009.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    17. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023 02; 42(9):693-707. Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN, Evans CP, Hammock BD, Liu C. PMID: 36596844; PMCID: PMC9975039.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    18. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Mol Cancer Ther. 2022 10 07; 21(10):1594-1607. Ning S, Liu C, Lou W, Yang JC, Lombard AP, D'Abronzo LS, Batra N, Yu AM, Leslie AR, Sharifi M, Evans CP, Gao AC. PMID: 35930737; PMCID: PMC9547958.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    19. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. Biomedicines. 2022 Jul 22; 10(8). Xu P, Wasielewski LJ, Yang JC, Cai D, Evans CP, Murphy WJ, Liu C. PMID: 35892678; PMCID: PMC9394279.
      View in: PubMed   Mentions: 24  
    20. Iron intake and multiple health outcomes: Umbrella review. Crit Rev Food Sci Nutr. 2023; 63(16):2910-2927. Huang Y, Cao D, Chen Z, Chen B, Li J, Wang R, Guo J, Dong Q, Liu C, Wei Q, Liu L. PMID: 34583608.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    21. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene. 2021 Sep; 40(35):5379-5392. Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. PMID: 34272475; PMCID: PMC8413131.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    22. Platinum-Containing Supramolecular Drug Self-Delivery Nanomicelles for Efficient Synergistic Combination Chemotherapy. Biomacromolecules. 2021 06 14; 22(6):2382-2392. Liu C, Li M, Li P, Chen W, Li H, Fan L, Tian W. PMID: 33905223.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    23. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 03 18; 11(1):6377. Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. PMID: 33737681; PMCID: PMC7973745.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    24. Correction to Supramolecular Drug-Drug Complex Vesicles Enable Sequential Drug Release for Enhanced Combination Therapy. ACS Appl Mater Interfaces. 2020 Sep 30; 12(39):44382. Liu C, Li C, Pang C, Li M, Li H, Li P, Fan L, Liu H, Tian W. PMID: 32935967.
      View in: PubMed   Mentions:    Fields:    
    25. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clin Cancer Res. 2020 11 15; 26(22):6064-6074. Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC. PMID: 32928794; PMCID: PMC7669645.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    26. Supramolecular Drug-Drug Complex Vesicles Enable Sequential Drug Release for Enhanced Combination Therapy. ACS Appl Mater Interfaces. 2020 Jun 24; 12(25):27940-27950. Liu C, Li C, Pang C, Li M, Li H, Li P, Fan L, Liu H, Tian W. PMID: 32449351.
      View in: PubMed   Mentions: 4     Fields:    Translation:Cells
    27. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Mol Cancer Ther. 2020 08; 19(8):1708-1718. Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, D'Abronzo LS, Evans CP, Gao AC, Liu C. PMID: 32430485; PMCID: PMC8855880.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    28. Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. Mol Cancer Ther. 2020 02; 19(2):364-374. Wang Y, Huang Z, Chen CZ, Liu C, Evans CP, Gao AC, Zhou F, Chen HW. PMID: 31712394.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    29. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol. 2019; 7(4):203-214. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC. PMID: 31511827; PMCID: PMC6734040.
      View in: PubMed   Mentions: 11  
    30. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Mol Cancer Ther. 2019 10; 18(10):1811-1821. Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans CP. PMID: 31341032.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    31. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2019 10; 18(10):1875-1886. Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC. PMID: 31308078; PMCID: PMC6995728.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    32. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul; 12(7):871-878. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. PMID: 31075528; PMCID: PMC6510951.
      View in: PubMed   Mentions: 19  
    33. An effective density-based clustering and dynamic maintenance framework for evolving medical data streams. Int J Med Inform. 2019 06; 126:176-186. Al-Shammari A, Zhou R, Naseriparsaa M, Liu C. PMID: 31029259.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. IFNγ, a Double-Edged Sword in Cancer Immunity and Metastasis. Cancer Res. 2019 03 15; 79(6):1032-1033. Liu C, Gao AC. PMID: 30877097.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    35. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 11 16; 9(1):4700. Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. PMID: 30446660; PMCID: PMC6240084.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
    36. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018 10; 17(10):2197-2205. Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. PMID: 29891490; PMCID: PMC6168406.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    37. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017 10; 16(10):2257-2266. Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. PMID: 28698198; PMCID: PMC5628132.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    38. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate. 2017 Jun; 77(9):1020-1028. Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. PMID: 28485104; PMCID: PMC5448975.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    39. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 08; 16(8):1521-1530. Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. PMID: 28500234; PMCID: PMC5544572.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    40. IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent manner. Sci Rep. 2016 11 04; 6:36002. Liu D, Cao T, Wang N, Liu C, Ma N, Tu R, Min X. PMID: 27812008; PMCID: PMC5095710.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    41. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017 01; 16(1):35-44. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. PMID: 27794047; PMCID: PMC5222693.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    42. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2016 May 31; 7(22):32210-20. Liu C, Armstrong C, Zhu Y, Lou W, Gao AC. PMID: 27049719; PMCID: PMC5078008.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    43. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther. 2015 Aug; 14(8):1884-95. Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. PMID: 26056150; PMCID: PMC4529751.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    44. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res. 2015 Sep 15; 21(18):4133-42. Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC. PMID: 25995342; PMCID: PMC4573793.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    45. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate. 2015 Sep; 75(13):1341-53. Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. PMID: 25970160; PMCID: PMC4536195.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    46. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015 Apr 01; 75(7):1413-22. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. PMID: 25649766; PMCID: PMC4383695.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansAnimalsCells
    47. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate. 2014 Aug; 74(11):1086-94. Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC. PMID: 24819501.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    48. Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer. 2014 Jun; 21(3):435-42. Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC. PMID: 24659479; PMCID: PMC4021715.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    49. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3198-3210. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. PMID: 24740322; PMCID: PMC4058390.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansAnimalsCells
    50. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar; 8(2):311-22. Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC, Wang Y. PMID: 24388358; PMCID: PMC5528545.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    51. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One. 2013; 8(11):e81050. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, Cai J, Li K. PMID: 24282568; PMCID: PMC3839885.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    52. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014 Feb; 74(2):201-9. Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC. PMID: 24307657; PMCID: PMC4437226.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    53. RhoGDIα downregulates androgen receptor signaling in prostate cancer cells. Prostate. 2013 Nov; 73(15):1614-22. Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC. PMID: 23922223; PMCID: PMC3941975.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    54. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013 Sep; 12(9):1829-36. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC. PMID: 23861346; PMCID: PMC3947549.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    55. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug; 12(8):1629-37. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. PMID: 23699654; PMCID: PMC3941973.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCells
    56. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013 03; 73(4):418-27. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC. PMID: 22996738; PMCID: PMC3938015.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    57. RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate. 2012 Mar; 72(4):392-8. Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Evans CP, Zhou Q, Gao AC. PMID: 21681778; PMCID: PMC3961824.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    58. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 2012 Jan; 72(1):82-9. Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC. PMID: 21538419; PMCID: PMC3938016.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    59. Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Mol Carcinog. 2012 Apr; 51(4):303-14. Liu C, Liu H, Li Y, Wu Z, Zhu Y, Wang T, Gao AC, Chen J, Zhou Q. PMID: 21520298.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    60. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011 Feb; 2(2):151-9. Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. PMID: 21779488; PMCID: PMC3111248.
      View in: PubMed   Mentions: 16  
    61. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010 Aug; 1(8):868-76. Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC. PMID: 21442031; PMCID: PMC3063649.
      View in: PubMed   Mentions: 25  
    62. [Selenium compounds induce ROS in human high-metastatic large cell lung cancer cell line L9981.]. Zhongguo Fei Ai Za Zhi. 2008 Jun 20; 11(3):354-8. Liu C, Chen J, Wu Z, Li Y, Zhu Y, Ren Y, Zhou Q. PMID: 20731933.
      View in: PubMed   Mentions: 2     Fields:    
    63. [The study of the tumorigenicity and metastasis ability in human lung cancer cell line L9981 using in vivo imaging.]. Zhongguo Fei Ai Za Zhi. 2008 Jun 20; 11(3):321-6. Ren Y, Chen J, Liu H, Yan H, Wang Y, Liu C, Zhou Q. PMID: 20731927.
      View in: PubMed   Mentions: 3     Fields:    
    Chengfei's Networks
    Concepts (212)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (24)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California